title: [Evaluation of risks related to human growth hormone (hGH) treatment. Results of an epidemiologic survey conducted in France of patients treated from 1959 to 1985].
abstract: Following the notification in the USA and England of four cases of Creutzfeldt-Jacob disease (MCJ) in patients previously treated with hGH, an epidemiological inquiry has been done in France to set up a clinical evaluation of all patients treated from 1959 to 1985. 1698 patients were registered for treatment. Current information (less than three months old) was obtained for 1622 patients (95.5%). Death was reported in 32 patients (2.0%), one is possibly related to a viral infection (malignant lymphoma), but none could be related to MCJ. Accidents were observed in 213 living patients (13.1%). Among them, 4 cases were classified as possibly related to a viral infection: acute lymphoid leukaemia, polyradiculoneuritis associated with hepatitis, acute encephalitis (2 cases). Even though the clinical symptomatology is not consistent with MCJ, a relationship with hGH therapy could not be completely excluded. Finally, six patients undertreatment developed malignancies. During the three last years, the question of side effects of hGH therapy has been raised in the literature two times running: risk of MCJ and risk of leukaemia. Then, the question of the long term vigilance of all treated patients with hGH deficiency should be done.
authors.affiliation: l'Unité INSERM 149 (Recherches Epidémiologiques sur la Mère et l'Enfant, Paris.
authors.forename: J
authors.initials: J
authors.lastname: Goujard
authors.forename: M
authors.initials: M
authors.lastname: Entat
authors.forename: F
authors.initials: F
authors.lastname: Maillard
authors.forename: E
authors.initials: E
authors.lastname: Mugnier
authors.forename: R
authors.initials: R
authors.lastname: Rappaport
authors.forename: J C
authors.initials: JC
authors.lastname: Job
mesh_terms: D007562:Creutzfeldt-Jakob Syndrome / Q000139:chemically induced; D003625:Data Collection; D005260:Female; D005602:France; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced
chemical_list: D013006:Growth Hormone
vernacular_title: Evaluation des risques liés au traitement par l'hormone de croissance humaine (hGH) extractive. Résultats de l'enquête épidémiologique menée en France sur les patients traités de 1959 à 1985.